Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what criteria the Accelerated Access Collaborative uses in relation to decision-making on (a) medicines, (b) diagnostic tools and (c) digital services.

The Accelerated Access Collaborative (AAC) is interested in supporting the most strategically important products that will have the biggest impact on patient health outcomes and delivery of National Health Service services.

When selecting products, the AAC will consider the following irrespective of innovation type (i.e. medicines, diagnostic tools, and digital products):

- evidence of clinical and cost effectiveness;

- addressing significant unmet need;

- application to large populations or high budget impact; and

- enabling a novel mode of action or enabling significant changes to the care pathway.

Further information is available at the following link:

https://www.nice.org.uk/aac